We further validated this finding with assays demonstrating a significantly lower IC50 of the JAK2-inhibitor ruxolitinib compared to TMZ in both gliosarcoma cultures, while the IC50 of ruxolitinib was modestly higher than TMZ in GBM1 (Figure 4C). This evidence concerns the gene JAK2 and gliosarcoma.